Drug Device Combination Products Market Size, Share & Trends Analysis Report By Product (Transdermal Patches, Inhalers, Infusion Pumps, Drug Eluting Stents, Antimicrobial Catheters)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global drug device combination products market size was exhibited at USD 129.32 billion in 2022 and is projected to hit around USD 303.35 billion by 2032, growing at a CAGR of 8.9% during the forecast period 2023 to 2032.

Key Pointers:

• North America held the dominant share of over 41.9% in 2022. 
• Asia Pacific is anticipated to grow at a lucrative rate over the forecast period.
• Transdermal patches emerged as the largest segment in 2022 with over 35.11% share.
• The inhalers segment is anticipated to exhibit a lucrative growth rate over the forecast period
• High operational cost, stringent regulatory framework, and capital requirements keep entry barriers at a higher level, owing to which, the threat of new entrants is expected to be low

Drug Device Combination Products Market Report Scope

increase in geriatric population and technological advancements in drug delivery systems are projected to boost the growth of the global market during the forecast period.

The rising incidence of chronic diseases such as chronic diseases and disorders, including cancer, diabetic retinopathy, cardiovascular diseases, colorectal cancer, asthma, and obesity, cardiac conditions, multiple sclerosis, etc. is a major factor expected to drive the global drug-device combination products market. Millions of people are suffering from chronic diseases across the globe. The rising geriatric population across the globe is also an important factor contributing to the market growth.

The major product types in the market include drug eluting stents, infusion pumps, photosensitizers, orthopedic combination products, wound care combination products, inhalers, transdermal patches, and others, which include intraocular implants and drug eluting beads. Growth of home-based healthcare industry and technological advancements such as development of prefilled syringes also contribute to market growth.

The global drug-device combination products market has been classified into drug eluting stents, infusion pumps, photosensitizers, orthopedic combination products, wound care combination products, inhalers, transdermal patches, and others. Transdermal patches are projected to be the most popular products in the upcoming years. This is due to increase in demand for self-administered drugs for diseases that require long-term treatment. Rising geriatric population across the globe is also creating value-grab opportunities for the companies operating in the drug device combination products market.

Insulin must be administered intravenously to diabetic patients on a regular basis. Repeated use of injections to deliver insulin causes pain and increases the risk of infection transmission. Hence, alternative drug delivery modes are expected to gain popularity. Drug-device combination products offer several advantages, which include reduced adverse side effects, improved patient compliance, controlled release administration of drug, and provide targeted drug delivery.

North America is expected to account for the largest share of the global drug-device combination products market. The North America market is significantly driven by rise in incidence of chronic diseases such as diabetes, cancer, and respiratory problems, increase in casualties, owing to accidents and trauma, and rise in geriatric population. Asia Pacific is also considered as the most lucrative market for drug-device combination products due to increase in incidences of cardiovascular diseases, diabetes-related disorders, and obesity. Moreover, improving healthcare infrastructure and high market potential in untapped emerging economies are anticipated to provide lucrative growth opportunities for Asia Pacific market players.

Some of the prominent players in the Drug Device Combination Products Market include:

• Abbott
• Terumo Corporation
• Stryker Corporation
• Mylan N.V.
• Medtronic
• Allergan plc
• Boston Scientific Corporation
• Novartis AG
• C.R. Bard
• Teleflex Incorporated
• W. L. Gore & Associates, Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Drug Device Combination Products market.

By Product 

• Infusion Pumps
  • Volumetric
  • Disposables
  • Syringes
  • Ambulatory
  • Implantable
  • Insulin
• Orthopedic Combination Products
  • Bone Graft Implants
  • Antibiotic Bone Cement
• Photodynamic Therapy Devices
• Transdermal Patches
• Drug Eluting Stents
  • Coronary Stents
  • Peripheral Vascular Stents
• Wound Care Products
• Inhalers
  • Dry Powder
  • Nebulizers
  • Metered Dose
• Antimicrobial Catheters
  • Urological
  • Cardiovascular
  • Others
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)